GILDKite, A Gilead CompanyFinished
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia · Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 95 (final count)
- Started
- Feb 1, 2016
- Main results expected
- Mar 25, 2026
- Fully finished
- Mar 25, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Percentage of Participants Experiencing Adverse Events Defined as Dose-Limiting Toxicities (DLT)
Measured over: Up to 28 days
Phase 2: Overall Complete Remission Rate in the ALL Cohort
Measured over: Up to 24 months
Phase 2: Objective Response Rate in the NHL Cohorts
Measured over: Up to 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02625480 · record last updated 2026-04-09 · checked 2026-11-09 15:47 UTC